Greater than the sum of our parts (Malaria case study)
Building climate-resilient, sustainable, and low-carbon health supply chains: key priorities for collective action
SafeBirth Africa: Reducing preventable deaths in childbirth
Maternal and newborn health
Unitaid and the Government of Spain
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Report (May 2018)
Fever Diagnostic Technology Landscape
Multi-disease diagnostics landscape for integrated management of HIV, HCV, TB and other coinfections
Hepatitis C medicines technology and market landscape
Unitaid’s approach to intellectual property
Discussion Paper: Ensuring that essential medicines are also affordable medicines: challenges and options
Discussion Paper: An economic perspective on delinking the cost of R&D from the price of medicines
Unitaid audited financial report for the year ended 31 December 2021
Unitaid audited financial report for the year ended 31 December 2020
Unitaid audited financial report for the year ended 31 December 2019
Unitaid audited financial report for the year ended 31 December 2018
Impact story: Improving use of tuberculosis diagnostics
Impact story: Improving severe malaria outcomes
Impact story: Accelerating access to seasonal malaria chemoprevention
Impact story: HIV Self-Testing
Impact story: Improved treatment for HIV: Dolutegravir
Impact story: Early-infant diagnosis of HIV using point-of-care technologies
Impact story: Medicines Patent Pool
Impact story: Childhood tuberculosis
